Clopidogrel HCS 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
1 issued on 
Decision 
Issued2 / 
amended 
on 
Information 
affected3 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/05/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0022/G 
This was an application for a group of variations. 
22/05/2017 
29/06/2017 
SmPC, 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union 
 
  
 
 
 
 
 
 
 
 
                                                
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0021/G 
This was an application for a group of variations. 
18/12/2015 
26/05/2016 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Clopidogrel HCS  
EMA/519077/2018 
Page 2/8 
  
  
 
 
 
the MAH 
R/0019 
Renewal of the marketing authorisation. 
26/03/2015 
16/06/2015 
Annex II 
Based on the review of available information, the CHMP is 
of the opinion that the quality, safety and efficacy of 
Clopidogrel HCS continues to be adequately and sufficiently 
demonstrated and considers that the benefit/risk profile of 
this medicinal product continues to be favourable. 
The product information has been updated to align with 
QRD templates.  The CHMP recommends that the renewal 
be granted with unlimited validity. 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/06/2015 
26/05/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0018/G 
This was an application for a group of variations. 
04/02/2015 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.d - Change in batch size (including batch size 
ranges) of AS or intermediate - More than 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
Clopidogrel HCS  
EMA/519077/2018 
Page 3/8 
  
  
 
 
 
 
 
 
 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
PSUSA/820/2
Periodic Safety Update EU Single assessment - 
10/07/2014 
n/a 
PRAC Recommendation - maintenance 
01311 
acetylsalicylic acid / clopidogrel, clopidogrel 
IB/0017/G 
This was an application for a group of variations. 
24/04/2014 
22/08/2014 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0014 
B.I.a.1.z - Change in the manufacturer of AS or of a 
09/04/2014 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0016 
C.I.8.a - Introduction of or changes to a summary of 
05/03/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Clopidogrel HCS  
EMA/519077/2018 
Page 4/8 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/01/2014 
22/08/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0012/G 
This was an application for a group of variations. 
21/10/2013 
22/08/2014 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0011/G 
This was an application for a group of variations. 
20/08/2013 
22/08/2014 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
II, Labelling 
and PL 
Clopidogrel HCS  
EMA/519077/2018 
Page 5/8 
  
  
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0010/G 
This was an application for a group of variations. 
25/05/2012 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the currently approved batch 
size 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0009 
B.II.a.3.z - Changes in the composition (excipients) 
26/03/2012 
24/10/2012 
SmPC and PL 
of the finished product - Other variation 
IB/0007/G 
This was an application for a group of variations. 
24/10/2011 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
Clopidogrel HCS  
EMA/519077/2018 
Page 6/8 
  
  
 
 
 
 
 
 
 
 
 
 
pharmaceutical group as the currently approved 
manufacturer 
IA/0008 
C.I.9.a - Changes to an existing pharmacovigilance 
28/09/2011 
n/a 
system as described in the DDPS - Change in the 
QPPV 
IB/0006 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
08/09/2011 
n/a 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/07/2011 
n/a 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0005 
A.7 - Administrative change - Deletion of 
19/07/2011 
n/a 
manufacturing sites 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/04/2011 
n/a 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
IA/0003/G 
This was an application for a group of variations. 
05/04/2011 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.h - Changes to an existing pharmacovigilance 
Clopidogrel HCS  
EMA/519077/2018 
Page 7/8 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
C.I.9.i - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
Clopidogrel HCS  
EMA/519077/2018 
Page 8/8 
  
  
 
  
